Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells
C Chu, D Armenia, C Walworth… - Clinical Microbiology …, 2022 - Am Soc Microbiol
SUMMARY HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …
[HTML][HTML] HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review
R Patel, L Evitt, I Mariolis, S Di Giambenedetto… - Infectious Diseases and …, 2021 - Springer
The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
[HTML][HTML] Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES …
Objectives The aim of this study was to assess the efficacy of dolutegravir plus lamivudine
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
(DTG+ 3TC) in a large set of virologically suppressed HIV-1 infected individuals with or …
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed …
Background Results from clinical trials and observational studies suggest that lamivudine
plus dolutegravir (3TC+ DTG) could be an effective and tolerated option for simplification in …
plus dolutegravir (3TC+ DTG) could be an effective and tolerated option for simplification in …
Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding
Background: Results from clinical trials and observational studies suggest that dolutegravir
plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 …
plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 …
Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in HIV treatment-experienced patients
F Olearo, H Nguyen, F Bonnet, S Yerly… - Open forum …, 2019 - academic.oup.com
Objective The impact of the M184V/I mutation on the virological failure (VF) rate in HIV-
positive patients with suppressed viremia switching to an abacavir/lamivudine/dolutegravir …
positive patients with suppressed viremia switching to an abacavir/lamivudine/dolutegravir …
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 …
D Rial-Crestelo, R de Miguel… - Journal of …, 2021 - academic.oup.com
Abstract Background In the ART-PRO pilot trial there were no virological failures through 48
weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and …
weeks of treatment with dolutegravir plus lamivudine in suppressed individuals with and …
[HTML][HTML] Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non …
R De Miguel, D Rial-Crestelo… - …, 2020 - thelancet.com
Background We investigated the efficacy of a switch to dolutegravir plus lamivudine in
aviremic individuals without evidence of persistent lamivudine resistance-associated …
aviremic individuals without evidence of persistent lamivudine resistance-associated …
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected …
N Galizzi, A Poli, L Galli, C Muccini… - International journal of …, 2020 - Elsevier
This was a retrospective study on the efficacy and drug resistance mutations selected at
virological failure (VF) in prospectively-followed HIV-infected patients switched to …
virological failure (VF) in prospectively-followed HIV-infected patients switched to …
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+ F/TAF or DTG+ F/tenofovir disoproxil fumarate (TDF) in the presence of …
RK Acosta, M Willkom, K Andreatta, H Liu… - JAIDS Journal of …, 2020 - journals.lww.com
Background: Study 4030 was a phase 3, randomized, double-blinded study of 565 HIV-1
RNA-suppressed participants switching to bictegravir/emtricitabine/tenofovir alafenamide …
RNA-suppressed participants switching to bictegravir/emtricitabine/tenofovir alafenamide …